This study analyzes Aspergillus isolates from the Spanish National Centre for Microbiology collection, which were identifi ed morphologically as members of Aspergillus section Usti . Strains were identifi ed through the analysis of the Internal Transcribed Spacer regions and partial tubulin gene sequences. One Aspergillus pseudodefl ectus isolate and eight Aspergillus calidoustus isolates were detected in this panel of clinical strains. Terbinafi ne and the echinocandins micafungin and anidulafungin, were the drugs most active against these species. The internal transcribed spacers (ITS) of the rDNA and a part of the tubulin gene (BenA) were sequenced for all Aspergillus isolates from our collection which were morphologically identifi ed as a member of section Usti . In addition, in vitro antifungal susceptibility testing was performed by means of EUCAST mold methodology [ 15 ] to assess their susceptibility profi les.
drugs [ 1 -10 ] . Recently, Houbraken et al . [ 1 ,2 ] proposed in their taxonomic review of this section that several strains, previously identifi ed as A. ustus , should be renamed as A. calidoustus .
The internal transcribed spacers (ITS) of the rDNA and a part of the tubulin gene (BenA) were sequenced for all Aspergillus isolates from our collection which were morphologically identifi ed as a member of section Usti . In addition, in vitro antifungal susceptibility testing was performed by means of EUCAST mold methodology [ 15 ] to assess their susceptibility profi les.
Material and methods

Strains
Nine strains were analyzed in this investigation, all held at the Mould Collection of the Spanish National Centre for Microbiology (CNM-CM) and previously identifi ed by morphological means as Aspergillus ustus . All were obtained from clinical samples, i.e., seven from respiratory sites, one from a vascular biopsy of an aneurysm and one from cerebrospinal fl uid. Each isolate was recovered from a different patient and sent to the Spanish Mycology Reference Laboratory for identifi cation and susceptibility testing. Strains were labelled as CNM-CM (Spanish National Centre for Microbiology-moulds culture collection), together with a unique identifi cation number. Three strains were acquired from the culture collection of the CBS-Fungal Biodiversity Centre, i.e., two A. ustus strains,
Introduction
Aspergillus section Usti has recently been reviewed on the basis of chemical, molecular and morphological data [ 1, 2 ] . Aspergillus insuetus , which had been synonymized with Aspergillus ustus [ 3 ] , has been revived and is currently a valid species. In addition, two new species have been described in the section Usti , i.e., Aspergillus keveii and Aspergillus calidoustus . Presently, Aspergillus section Usti includes the following species: Aspergillus ustus , Aspergillus puniceus , Aspergillus granulosus , Aspergillus pseudodefl ectus , Aspergillus calidoustus , Aspergillus insuetus , Aspergillus keveii and Emericella heterothallica.
During recent years there have been several reports on the clinical importance of A. ustus . Twenty-four cases have been reported in the literature since 1971, half of them in the last three years [ 4 -7 ] . Infections due to A. ustus have been associated with high mortality rates, and examination of its in vitro antifungal susceptibility profi le reveals high MIC (minimum inhibitory concentration) values for many CNM-CM4036 (CBS 113233) of unknown origin and CNM-CM4037 (CBS 239.90) from a brain abscess and one A. pseudodefl ectus strain CNM-CM5302 (CBS 756.74) of environmental origin.
Morphological identifi cation
The strains were subcultured on different agar media to ascertain their macroscopic and microscopic morphology. The media included malt extract agar (MEA, 2% malt extract, Oxoid S.A., Madrid, Spain) and Czapek-Dox Agar (Soria Melgizo S.A., Madrid, Spain, Difco 0339-01-1). Cultures were incubated at 30°C and 37°C.
PCR and DNA sequencing of ITS region
Moulds were cultured in GYEP medium (0.3% yeast extract, 1% peptone, Difco, Soria Melguizo S.A) with 2% glucose (Sigma-Aldrich Quimica, Madrid, Spain), for 24-48 h at 30°C. Genomic DNA was isolated using an extraction procedure previously described [ 11 ] .
DNA segments comprising the ITS1 and ITS2 regions were amplifi ed with primer set ITS1 (5´-TCCGTAGGT GAACCTGCGG-3´) and ITS4 (5´-TCCTCCGCTTATT GATATGC-3´) [ 12 ] . Partial sequence of the β-tubulin gene was amplifi ed using primer set βtub3 (5´-TTCACCTTC AGACCGGT-3´) and βtub2 (5´-AGTTGTCGGGACGGA ATAG-3´) [ 13 ] . All primers were synthesized by Sigma Genosys (Madrid, Spain). The reaction mixtures for ITS amplifi cation contained 0.5 μM of each primer; 0.2 mM of each deoxynucleoside triphosphate (Applied Biosystems, Madrid, Spain); 5 μl of PCR 10 × buffer (Applied Biosystems); 2.5 U Taq DNA polymerase (Applied Biosystems); and 25 ng of genomic DNA in a fi nal volume of 50 l. For the portion of β tubulin, PCRs were run with a volume of 50 l containing 1 μM of each primer; 250 M of each deoxynucleoside triphosphate (Applied Biosystems); 1 × PCR buffer (Applied Biosystems); 2 mM MgCl 2 (Applied Biosystems); 2.5 U of Taq DNA polymerase (Applied Biosystems); and 25 ng of genomic DNA. Amplifi cation was performed in a thermal cycler (GeneAmp PCR system 9700; Applied Biosystems) using the following cycling parameters: for ITS one initial cycle of 2 min at 94°C, followed by 35 cycles of 30 s at 94°C, 45 s at 56°C, and 2 min at 72°C, with one fi nal cycle of 5 min at 72°C; for β tubulin 1 cycle of 5 min at 94°C and then 30 cycles of 30 s at 94°C, 45 s at 55°C, and 1-2 min at 72°C, followed by 1 fi nal cycle of 10 min at 72°C. The PCR products were analyzed by electrophoresis on 0.8% agarose gels and visualized by transillumination (Gel Doc 2000; Bio-Rad Laboratories, Madrid, Spain) after staining with ethidium bromide (Sigma-Aldrich Quimica).
The sequencing reactions were undertaken as described previously [ 14 ] , with 2 μl of reaction mixture from a sequencing kit (BigDye terminator cycle sequencing kit, Ready Reaction mixture; Applied Biosystems), 1 M of the primers, and 3 l of the PCR product in a fi nal volume of 10 l. The primers used for sequencing were ITS1 and ITS4 for the ITS region and tub1 (AATTGGTGC CGCTTTCTGG) and βtub4 (5´-AGCGTCCATGGTAC CAGG-3´) [ 13 ] for the β-tubulin gene. Sequences were assembled and edited using the SeqMan II and EditSeq software packages (Lasergene: DNAstar, Inc., Madison, Wisconsin, USA).
Identifi cation and phylogenetic analysis
Identifi cations were based on comparisons of the sequences with ITS and β tubulin sequences of Aspergillus section Usti strains obtained from the GenBank database. The phylogenetic analyses were conducted with InfoQuest FP software, version 4.50 (BIORAD Laboratories, Madrid, Spain). The methodology used was maximum parsimony clustering. Phylogram stability was assessed by parsimony bootstrapping with 2000 simulations. Aspergillus fumigatus CNM-CM237 was used as an outgroup to root the phylograms.
GenBank accession numbers
Following are the GenBank accession numbers for β tubulin fragment sequence from the strains included in this work: CBS121601 FJ624456; CNM-CM2105 FJ624457; CNM-CM2272 FJ624458; CNM-CM237 FJ624459; CNM-CM2475 FJ624460; CNM-CM3788 FJ624461; CNM-CM3927 FJ624462; CNM-CM4036 FJ624463; CNM-CM4037 FJ624464; CNM-CM4115 FJ624465; CNM-CM4212 FJ624466; CNM-CM5070 FJ624467
Antifungal susceptibility testing
Microdilution testing was performed following the EUCAST standard methodology [15] [16] [17] [18] . Aspergillus fumigatus ATCC 2004305 and Aspergillus fl avus ATCC 2004304 were used as quality control strains [ 19 ] .
The following antifungal agents were tested: Amphotericin B (Sigma-Aldrich Quimica), itraconazole (Janssen Pharmaceutica, Madrid, Spain); voriconazole (Pfi zer S.A., Madrid, Spain); ravuconazole (Bristol-Myers Squibb, Princeton, USA); posaconazole (Schering-Plough Research Institute, Kenilworth, NJ); terbinafi ne (Novartis, Basel, Switzerland); caspofungin (Merck & Co., Inc., Rahway, NJ); micafungin (Astellas pharma Inc., Tokio, Japan) and anidulafungin (Pfi zer S.A.). The fi nal concentrations tested range from 16 to 0.03 mg/l for amphotericin B, terbinafi ne, caspofungin and anidulafungin, and from 8 to 0.015 mg/l for itraconazole, voriconazole, ravuconazole and posaconazole. The plates were incubated at 35°C for 48 h in a humid atmosphere. Visual readings were performed with the help of a mirror. The endpoint for amphotericin B, itraconazole, voriconazole, ravuconazole, posaconazole and terbinafi ne was defi ned as the antifungal concentration that produced a complete inhibition of visual growth at 48 h. For the echinocandins the endpoint was the antifungal concentration that produced a visible change in the morphology of the hyphae as compared with the growth in control well (minimum effective concentration, MEC) [ 20 ,21 ] . The antifungal susceptibility testing was repeated at least three times on different days for each isolate.
Results
Identifi cation of strains
Morphological examination showed that all nine isolates were members of Aspergillus section Usti . All grew at 30 and 37°C in contrast with the A. ustus strains from the CBS culture collection,which were not able to grow at 37°C. The identifi cation to species level was assessed by molecular methods, analyzing the ITS regions (data not shown) and partial β tubulin gene sequences ( Fig. 1 ) . Eight out of nine strains were identifi ed as A. calidoustus and one as A. pseudodefl ectus (CNM-CM5070). No other species were found in this collection of clinical isolates. The tubulin sequence was the only characteristic that differed between A. calidoustus and A. pseudodefl ectus. Both species shared the same ITS sequence and are able to grow at 37°C.
Antifungal susceptibility testing
The geometric mean (GM) and range of the MICs of antifungal agents for each isolate is shown in Table 1 . Due to the limited number of isolates, a susceptibility pattern could not be obtained. In any case, anidulafungin and micafungin have excellent activity in vitro against all isolates shown in Table 1 . Amphotericin B also shows signifi cant activity in vitro against the clinical isolates, with the exception of one A. ustus and one A. calidoustus isolate. Finally, only one A. pseudodefl ectus isolate showed high MICs against terbinafi ne. Fig. 1 Phylogenetic tree of the subset of isolates included in the study obtained by using maximum parsimony phylogenetic analyses and 2000 bootstrap simulations based on a portion of the tubulin sequences. Aspergillus fumigatus CNM-CM237 was used as an outgroup to root the tree.
Table 1
Geometric mean (GM) and range of MICs (mg/l) of antifungal agents tested in the study. [ 4 ,10 ] . However, no data has been found so far on in vitro activity of micafungin and anidulafungin. These two new echinocandins can be useful for the treatment of these fungi, as the in vitro susceptibility testing has shown. In addition, this study as well as another report [ 4 ] , have shown effective action of amphotericin B against this group of fungi ( Table 1 ). In summary, identifi cation at species level for Aspergillus species has become an important issue since species with high in vitro MICs have been increasingly involved in fungal infections. A. calidoustus is a recently described, multi-resistant fungus that can be found in clinical samples, and can be accurately identifi ed at species level by sequencing a part of the β tubulin gene. Optimal treatment for these infections has not been established yet. Susceptibility testing should therefore be performed in order to provide alternatives for the treatment of this infection.
